Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study


Por: Sirven, MB, López-Knowles, E, Zhu, XX, Tovey, H, Kilburn, L, Holcombe, C, Skene, A, Robertson, J, Bliss, JM, Alataki, A, Smith, I, Schuster, EF, Dowsett, M and Cheang, MCU

Publicada: 1 ago 2025 Ahead of Print: 1 ago 2025
Resumen:
Background: About 15-20% of breast cancers (BC) overexpress Human Epidermal Growth Factor Receptor 2 (HER2+), and 50% of them are also oestrogen receptor positive (ER+). Patients with ER+/HER2+ BC with a limited response to systemic therapies are at an increased risk of relapse, thus understanding the mechanisms of resistance is crucial. This study investigates the changes in gene signature expression (Delta GSE) within ER+/HER2+ tumours and their intrinsic subtype (IS) in response to peri-operative aromatase inhibitors (POAI). Methods: We analysed paired pre-treatment (baseline) and on-treatment (2wk) samples from 313 ER+/HER2+ BC from the POETIC trial using the BC360 (TM) codeset. Early biological response to aromatase inhibitors (AI) was assessed by immunohistochemical Ki67 levels. Association of Delta GSE with biological response was evaluated using T-test and time to recurrence (TTR) with multivariable Cox regression models adjusted for clinicopathological variables. Findings: The immunity-related signatures were significantly upregulated, while proliferation, TP53 surrogate mutational status and ER-signalling were downregulated (FDR <005) among POAI tumours with low Ki67(2)(wk). In the POAI, 79% (59/75) of Luminal B (LumB) at baseline shifted to Luminal A (LumA) at 2wk and LumA(2)(wk) was associated with better TTR compared to LumB(2)(wk) (HR 02; CI 95% 006-072, p = 001). Based on Akaike Information Criterion scores, Ki67 and IS at 2wk provided better fit of the multivariable Cox models over the variables at baseline when predicting TTR. Interpretation: Assessing on-treatment IS after POAI for ER+HER2+ BC can help to identify a group of low-risk patients with LumA(2)(wk) with good outcomes on de-escalated treatment and patients that require additional treatments.

Filiaciones:
:
 Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, London, England

 Hosp Germans Trias & Pujol HGTiP, Catalan Inst Oncol Badalona, Med Oncol Dept, Badalona 08916, Spain

 Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

López-Knowles, E:
 Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England

 Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England

Zhu, XX:
 Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, London, England

Tovey, H:
 Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, London, England

Kilburn, L:
 Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, London, England

Holcombe, C:
 Liverpool Univ Hosp Fdn Trust, Liverpool, England

Skene, A:
 Royal Bournemouth & Christchurch NHS Fdn Trust, Bournemouth, England

Robertson, J:
 Queens Med Ctr, Fac Med & Hlth Sci, Nottingham, England

Bliss, JM:
 Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, London, England

Alataki, A:
 Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England

 Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England

Smith, I:
 Royal Marsden Hosp, London, England

Schuster, EF:
 Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England

 Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England

Dowsett, M:
 Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England

Cheang, MCU:
 Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, London, England
ISSN: 23523964





EBioMedicine
Editorial
Elsevier BV, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Reino Unido
Tipo de documento: Article
Volumen: 118 Número:
Páginas: 105823-105823
WOS Id: 001582391400003
ID de PubMed: 40683772
imagen Green Submitted, gold

MÉTRICAS